Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Status:
Active, not recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This research study is studying a drug as a possible treatment for High Grade Meningioma.
The drug involved in this study is an immunotherapy drug called pembrolizumab